Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 USD | -0.87% | +0.88% | +12.87% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
May. 14 | Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on Passage Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Passage Bio, Inc.
Canaccord Genuity | |
Wedbush | |
Chardan Research | |
Raymond James | |
Guggenheim | |
Citigroup | |
Goldman Sachs | |
JPMorgan Chase | |
BTIG | |
Chardan |
EPS Revisions
- Stock Market
- Equities
- PASG Stock
- Consensus Passage Bio, Inc.